News & Updates

At the second interim analysis of part 1 of the phase III RUBY study, updated duration of response (DoR) findings suggest that women with primary advanced or recurrent endometrial cancer who have achieved a response with the combination regimen comprising dostarlimab and carboplatin-paclitaxel (CP) have substantially improved DoR.

Testosterone recovery to a normal level appears predictive of improved overall survival (OS) among men with intermediate-risk prostate cancer who underwent androgen-deprivation therapy (ADT) and radiation therapy (RT), suggests a study.

Initial results of the phase I RUTIVAC-1 study show the potential of two doses of a tuberculosis (TB) vaccine given after surgery but before standard BCG* treatment to boost immunity and reduce the odds of recurrence in patients with non-muscle-invasive bladder cancer (NMIBC).

The health-related quality of life (QOL) trajectories for colorectal cancer (CRC) patients are largely similar, regardless of whether they received adjuvant chemotherapy, according to a study from Singapore. However, CRC patients who undergo adjuvant treatments commonly experience difficulties with functional recovery.